drugset / Trial / NCT02138929
LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma
Phase 1
Completed
25 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of LDE225 that can be given in combination with everolimus to patients with esophageal or GEJ cancer. The safety of the drug combination will also be studied.
Timeline
- Start
- 2014-11-10
- Primary completion
- 2020-06-08
- Completion
- 2020-06-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | Sonidegib | Small molecule | 200 mg | Oral |
| Subject | Sonidegib | Small molecule | 400 mg | Oral |
| Subject | Sonidegib | Small molecule | 800 mg | Oral |